Copertina

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jiru Li, Qi‐En Shen
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
di: Mohamed El‐Kassas, et al.
Pubblicazione: (2025)

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
di: Hassan Javed, et al.
Pubblicazione: (2025)

Lubiprostone Reduces Fat Content on MRI‐PDFF in Patients With MASLD: A 48‐Week Randomised Controlled Trial
di: Mohamed El‐Kassas, et al.
Pubblicazione: (2025)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
di: Yuki Utakata, et al.
Pubblicazione: (2026)

Letter: A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
di: Xiaojuan Liu, et al.
Pubblicazione: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing?
di: Qiang Hu, et al.
Pubblicazione: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
di: Stuart McPherson, et al.
Pubblicazione: (2024)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations
di: Christophe Corpechot
Pubblicazione: (2026)

Letter: Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time‐Restricted Feeding in MASLD Management—Authors' Reply
di: Sofia Tsitsou, et al.
Pubblicazione: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
di: Yewan Park, et al.
Pubblicazione: (2024)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
di: Zhejin Shi, et al.
Pubblicazione: (2026)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
di: Zhanbo Qu
Pubblicazione: (2026)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
di: J. M. Schattenberg, et al.
Pubblicazione: (2026)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
di: Wenjun Meng, et al.
Pubblicazione: (2024)

Letter: MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls
di: Junbin Yan, et al.
Pubblicazione: (2024)

Letter: Exclusive Enteral Nutrition in Ulcerative Colitis—The Path Ahead Needs Careful Consideration
di: Sarah Melton, et al.
Pubblicazione: (2025)

Letter: Optimising Targeted Next‐Generation Sequencing for Intestinal Tuberculosis Diagnosis—Methodological Considerations
di: Haleema Rahman
Pubblicazione: (2025)

Letter on ‘Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study’
di: Muhammad Abubakr, et al.
Pubblicazione: (2025)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
di: Kaleb Tesfai, et al.
Pubblicazione: (2026)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
di: Chachrit Khunsriraksakul, et al.
Pubblicazione: (2025)

Editorial: Beyond Clinical Trials—Real‐World Data Suggest Usefulness of GLP‐1 RAs in MASLD Treatment. Authors' Reply
di: Chia‐Chih Kuo, et al.
Pubblicazione: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Considerations for Outcome Measurement and Clinical Interpretation
di: Dingsheng Liu, et al.
Pubblicazione: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
di: Jia‐Yong Su, et al.
Pubblicazione: (2025)

Editorial: Hyperferritinaemia—An Ironclad Biomarker for the Prognostication of MASLD?
di: Mark C. C. Cheah, et al.
Pubblicazione: (2025)

Editorial: Cardiometabolic criteria matters inMASLD
di: Margaret L. P. Teng, et al.
Pubblicazione: (2024)

Letter: Beyond Survival Benefit in CHANCE2311—Important Considerations in the Interpretation of TACE Combined With Immunotherapy in Advanced HCC
di: Yinghan Chen, et al.
Pubblicazione: (2026)

Letter: Dynamic HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation: Considerations in Interpreting Predictive Performance
di: Hsiang‐Ting Keng, et al.
Pubblicazione: (2026)

Editorial: NAFLD, NAFLD, or MASLD: what's in a name?
di: Maryam Zafer, et al.
Pubblicazione: (2024)

Letter: Methodological Considerations in Comparing Liver Outcomes of Glucagon‐Like Peptide‐1 Receptor and Sodium Glucose Cotransporter‐2 Inhibitors
di: Cheng‐Hsien Hung, et al.
Pubblicazione: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
di: Jeffrey D. McCurdy, et al.
Pubblicazione: (2025)

Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)!
di: Hannah Mohr, et al.
Pubblicazione: (2025)

Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography ( GOLDMINE ): A Multi‐Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes
di: Suzanne Sharpton, et al.
Pubblicazione: (2026)

Editorial: Accelerometers to Quantify Physical Activity in MASLD—Impact on Clinical Outcomes
di: Vincent L. Chen
Pubblicazione: (2025)

Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof‐Of‐Concept Study
di: R. Sinha, et al.
Pubblicazione: (2025)

Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
di: Wah‐Kheong Chan, et al.
Pubblicazione: (2024)

Letter: Differences in Disease Characteristics and Treatment Exposures Between Paediatric and Adult‐Onset IBD
di: Xinli Chen, et al.
Pubblicazione: (2024)

Letter: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
di: Jiaqi Shen, et al.
Pubblicazione: (2026)

Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT ‐ UC Consortium
di: Brian C. Weiner
Pubblicazione: (2025)

Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC
di: Xiaosong Li, et al.
Pubblicazione: (2024)